Cancer Research Communications
Overview
Cancer Research Communications is a scientific journal, published since 2021 in English. The journal's country of origin is United States and its primary focus area is oncology.
Details
Details
Abbr.
Cancer Res Commun
Start
2021
End
Continuing
Frequency
Monthly, 2022-
e-ISSN
2767-9764
Country
United States
Language
English
Specialty
Oncology
Recent Articles
1.
Yang X, Mosha M, Bell D, Dean J, Mayer J, Amankwah E
Cancer Res Commun
. 2025 Mar;
PMID: 40066853
Limited knowledge exists on the prevalence of comorbidity among pediatric patients diagnosed with acute lymphoblastic leukemia (ALL) or lymphoblastic lymphoma (LL). To determine the prevalence of comorbidities present within 3...
2.
Natale C, Mercado S, Zhuang R, Aguirre-Portoles C, Olayide I, Arnatt C, et al.
Cancer Res Commun
. 2025 Mar;
PMID: 40066851
Estrogen effects in tissue are mediated in part through activation of the surface estrogen receptor GPER, a broadly expressed G protein-coupled receptor that impacts a wide range of normal and...
3.
Lusk H, Haughan M, Bergsten T, Burdette J, Sanchez L
Cancer Res Commun
. 2025 Mar;
PMID: 40066850
Ovarian cancer is the sixth leading cause of cancer-related mortality among individuals with ovaries, and high-grade serous ovarian cancer (HGSOC) is the most common and lethal subtype. Characterized by a...
4.
Taheri H, Li Y, Huang K, Ahmed E, Jin Y, Drabison T, et al.
Cancer Res Commun
. 2025 Mar;
PMID: 40062557
Aromatase inhibitors (AIs) such as anastrozole, letrozole and exemestane are used as adjuvant treatment for postmenopausal women with hormone receptor-positive breast cancer. The interindividual pharmacokinetic variability seen with AIs is...
5.
Chelariu-Raicu A, Vu T, Umamaheswaran S, Stur E, Hanjra P, Han Y, et al.
Cancer Res Commun
. 2025 Mar;
PMID: 40029935
Antibodies targeting folate receptor 1 (FOLR1) induce autophagic cell death in addition to antibody-dependent cytotoxicity, but the biological relevance of anti-FOLR1 antibody-induced autophagy for clinical applications remains unclear. Here, we...
6.
Patel S, Cook R, Lo J, Cherry F, Hoogenboezem E, Yu F, et al.
Cancer Res Commun
. 2025 Feb;
PMID: 40019775
Alterations in the phosphatidylinositol 3-kinase (PI3K) signaling / mammalian target of rapamycin (mTOR) signaling pathway are often seen in triple negative breast cancers (TNBCs), a breast cancer subtype characterized by...
7.
Jackson C, Liu J, Liu H, Williams S, Anees A, Noor Z, et al.
Cancer Res Commun
. 2025 Feb;
PMID: 40014866
Although HPV-positive OPSCC is associated with better prognosis than HPV-negative disease, ~30% of cases relapse despite curative-intent radiotherapy (+/- chemotherapy). We aimed to develop a proteomic signature associated with risk...
8.
Tang W, Ma X
Cancer Res Commun
. 2025 Feb;
5(3):433-443.
PMID: 39991825
In this study, we identified several causal proteins in HCC using UK Biobank Pharma Proteomics Project proteomic data via two-sample MR. We performed colocalization and sensitivity analyses, utilized single-cell RNA...
9.
Gambardella V, Ong M, Rodriguez-Ruiz M, Machiels J, Sanmamed M, Galvao V, et al.
Cancer Res Commun
. 2025 Feb;
5(3):422-432.
PMID: 39983024
Purpose: Therapeutic depletion of immunosuppressive regulatory T cells (Treg) may overcome resistance to cancer immunotherapies. RG6292 is an anti-CD25 antibody that preferentially depletes Tregs while preserving effector T-cell functions in...
10.
Landi D, Navai S, Brock R, Fousek K, Nawas Z, Sanber K, et al.
Cancer Res Commun
. 2025 Feb;
PMID: 39973814
The efficacy of CAR T-cells (CART) in solid tumors is limited by immune inhibition. In our study, we observed that effector cytokines mediated the upregulation of the PD-L1 immune-checkpoint in...